CTIM-76 Phase 1 clinical trial to focus on CLDN6-positive gynecologic and testicular cancers
Company expects to enroll first patient in mid-2024
https://www.globenewswire.com/news-release/2024/05/02/2874098/0/en/Context-Therapeutics-Announces-FDA-Clearance-of-IND-Application-for-a-Phase-1-Clinical-Trial-of-CTIM-76.html
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.